- Home
- GILD vs SYK Comparison
GILD vs SYK Comparison
Compare GILD & SYK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- SYK
- Stock Information
- Founded
- GILD 1987
- SYK 1941
- Country
- GILD United States
- SYK United States
- Employees
- GILD N/A
- SYK N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- SYK Medical/Dental Instruments
- Sector
- GILD Health Care
- SYK Health Care
- Exchange
- GILD Nasdaq
- SYK Nasdaq
- Market Cap
- GILD 139.6B
- SYK 144.9B
- IPO Year
- GILD 1992
- SYK N/A
- Fundamental
- Price
- GILD $113.62
- SYK $377.67
- Analyst Decision
- GILD Buy
- SYK Buy
- Analyst Count
- GILD 23
- SYK 19
- Target Price
- GILD $116.36
- SYK $428.50
- AVG Volume (30 Days)
- GILD 5.9M
- SYK 944.2K
- Earning Date
- GILD 11-05-2025
- SYK 10-28-2025
- Dividend Yield
- GILD 2.78%
- SYK 0.89%
- EPS Growth
- GILD 496.80
- SYK N/A
- EPS
- GILD 5.01
- SYK 7.55
- Revenue
- GILD $28,863,000,000.00
- SYK $23,818,000,000.00
- Revenue This Year
- GILD $2.07
- SYK $11.74
- Revenue Next Year
- GILD $3.95
- SYK $8.51
- P/E Ratio
- GILD $22.69
- SYK $50.04
- Revenue Growth
- GILD 3.81
- SYK 11.36
- 52 Week Low
- GILD $81.83
- SYK $329.16
- 52 Week High
- GILD $121.83
- SYK $406.19
- Technical
- Relative Strength Index (RSI)
- GILD 48.34
- SYK 40.51
- Support Level
- GILD $110.15
- SYK $381.51
- Resistance Level
- GILD $114.13
- SYK $381.19
- Average True Range (ATR)
- GILD 2.28
- SYK 6.50
- MACD
- GILD -0.31
- SYK -1.69
- Stochastic Oscillator
- GILD 43.59
- SYK 18.65
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About SYK Stryker Corporation
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.